Lumos Achieves 250 Patient Milestone in FebriDx® Paediatric Study
14 May 2026
Lumos has achieved enrolment of 250 patients in its BARDA-funded FebriDx® paediatric clinical study, triggering a US$670,000 milestone payment.
The study is evaluating the use of FebriDx® in children aged 2–12 years within CLIA-waived healthcare settings in the US and supports the potential expansion of FebriDx® into paediatric respiratory infection management.
Total milestone payments received under the BARDA paediatric agreement now stand at US$2.59 million, with BARDA having committed up to US$6.2 million across all study milestones.
This work builds on the recent FDA 510(k) clearance and CLIA waiver granted for FebriDx® use in patients aged 12–64 years.
Lumos CEO Doug Ward said:
“The paediatric study continues to progress, and we look forward to the day that we can support clinicians in accurately assessing acute respiratory infections in younger children.”
Click to read the ASX announcement.
The study is evaluating the use of FebriDx® in children aged 2–12 years within CLIA-waived healthcare settings in the US and supports the potential expansion of FebriDx® into paediatric respiratory infection management.
Total milestone payments received under the BARDA paediatric agreement now stand at US$2.59 million, with BARDA having committed up to US$6.2 million across all study milestones.
This work builds on the recent FDA 510(k) clearance and CLIA waiver granted for FebriDx® use in patients aged 12–64 years.
Lumos CEO Doug Ward said:
“The paediatric study continues to progress, and we look forward to the day that we can support clinicians in accurately assessing acute respiratory infections in younger children.”
Click to read the ASX announcement.
